Post-Traumatic Stress Disorder (PTSD) Research
The Mood and Anxiety Disorders Program (MAP) is researching a range of new treatments for post-traumatic stress disorder (PTSD). Our studies include research into finding novel uses for current medications such as ketamine (an FDA-approved anesthetic) and developing new drugs.
Clinical Trials for Post-Traumatic Stress Disorder (PTSD)
MAP is currently seeking individuals interested in participating in the following clinical trials for PTSD.
- An inhibitor of the “stress hormone” (corticotropin releasing factor antagonist) for the Treatment of PTSD: Investigates the efficacy of using a corticotropin releasing factor antagonist to inhibit the release of stress hormones in patients with PTSD.
- Intranasal Administration of Neuropeptide Y in PTSD: Studies the antidepressant and anti-anxiety effect of intranasal administration of neuropeptide Y (NPY) for patients with post-traumatic stress disorder (PTSD).
To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact Sarah Horn (212-241-7910, firstname.lastname@example.org).